Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.
作者信息
Herder Matthew
机构信息
Faculty of Medicine, Dalhousie University, Halifax, NS.
出版信息
CMAJ. 2012 Feb 7;184(2):194-9. doi: 10.1503/cmaj.110721. Epub 2011 Aug 29.
Abstract
摘要
相似文献
1
Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.揭开加拿大卫生部商业机密的面纱：临床试验结果的强制披露
CMAJ. 2012 Feb 7;184(2):194-9. doi: 10.1503/cmaj.110721. Epub 2011 Aug 29.
2
Clinical trial data as a public good.作为公共产品的临床试验数据。
JAMA. 2012 Sep 5;308(9):871-2. doi: 10.1001/jama.2012.9661.
3
Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.医学研究中的保密法与保密性：改善公众获取药物安全数据的途径
Health Aff (Millwood). 2007 Mar-Apr;26(2):483-91. doi: 10.1377/hlthaff.26.2.483.
4
AbbVie considers harms to be commercially confidential information: sign a petition.艾伯维公司认为危害信息属于商业机密信息：签署一份请愿书。
BMJ. 2013 Dec 23;347:f7569. doi: 10.1136/bmj.f7569.
5
Regulatory transparency: social, technical, and ethical aspects of clinical trial data access.监管透明度：临床试验数据获取的社会、技术和伦理方面
Rev Panam Salud Publica. 2015 Jun;37(6):430-4.
6
Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.可预测的重要性：对规范上市公司披露临床试验结果的通用标准的需求。
J Contemp Health Law Policy. 2013 Spring;29(2):201-32.
7
Manufacturers' promotion of off-label drug use: implications for drug safety.制造商对药品非标签使用的推广：对药物安全性的影响。
Expert Opin Drug Saf. 2016 Sep;15(9):1149-51. doi: 10.1080/14740338.2016.1186642. Epub 2016 May 23.
8
Drug companies should release data from all trials of licensed drugs, say MPs.议员们表示，制药公司应该公布已获许可药物所有试验的数据。
BMJ. 2013 Jan 16;346:f321. doi: 10.1136/bmj.f321.
9
Dispute over use of MDs' prescribing information heading to court.关于医生处方信息使用的争议即将诉诸法庭。
CMAJ. 2003 Feb 4;168(3):325.
10
NICE is urged to make drug companies supply all trial data.英国国家卫生与临床优化研究所（NICE）被敦促要求制药公司提供所有试验数据。
BMJ. 2012 Dec 5;345:e8294. doi: 10.1136/bmj.e8294.
引用本文的文献
1
How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines.如何利用加拿大卫生部的监管数据对新药、生物制品和疫苗进行二次分析。
BMJ Evid Based Med. 2024 May 22;29(3):187-193. doi: 10.1136/bmjebm-2023-112475.
2
On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data.1996 年加拿大卫生部批准奥施康定的依据是什么？监管数据的回顾性分析。
Clin Trials. 2022 Oct;19(5):584-590. doi: 10.1177/17407745221108436. Epub 2022 Aug 4.
3
North American regulatory agencies can and should make clinical trial data publicly available.北美监管机构能够且应该公开临床试验数据。
CMAJ. 2016 Feb 2;188(2):96-97. doi: 10.1503/cmaj.150679. Epub 2015 Oct 13.
4
Health Canada's use of its priority review process for new drugs: a cohort study.加拿大卫生部对新药使用优先审评程序的队列研究。
BMJ Open. 2015 May 11;5(5):e006816. doi: 10.1136/bmjopen-2014-006816.
5
Quality and quantity of information in summary basis of decision documents issued by health Canada.加拿大卫生部发布的决策文件总结依据中的信息质量和数量。
PLoS One. 2014 Mar 20;9(3):e92038. doi: 10.1371/journal.pone.0092038. eCollection 2014.
6
Regulating prescription drugs for patient safety: does Bill C-17 go far enough?为保障患者安全规范处方药：C-17法案力度够吗？
CMAJ. 2014 May 13;186(8):E287-92. doi: 10.1503/cmaj.131850. Epub 2014 Mar 10.
7
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.加拿大上市后安全性：重大治疗进展药物和生物制品是否比其他药物安全性更低？一项队列研究。
BMJ Open. 2014 Feb 18;4(2):e004289. doi: 10.1136/bmjopen-2013-004289.
8
Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship.加拿大卫生部与制药行业：历史关系的初步分析
Healthc Policy. 2013 Nov;9(2):22-9.
本文引用的文献
1
Withdrawal of clinical trials policy by Canadian research institute is a "lost opportunity for increased transparency".加拿大研究机构撤回临床试验政策是“提高透明度的一个错失的机会”。
BMJ. 2011 Apr 21;342:d2570. doi: 10.1136/bmj.d2570.
2
Can Health Canada protect Canadians from unsafe drugs?加拿大卫生部能保护加拿大人免受不安全药物的危害吗？
CMAJ. 2011 Jul 12;183(10):1125-6. doi: 10.1503/cmaj.110489. Epub 2011 Apr 18.
3
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.提交给美国食品药品监督管理局的药物试验中的报告偏倚：发表与呈现情况综述
PLoS Med. 2008 Nov 25;5(11):e217; discussion e217. doi: 10.1371/journal.pmed.0050217.
4
Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.试验注册与结果披露：美国立法对申办者、研究者及医学期刊编辑的影响。
Curr Med Res Opin. 2008 Jun;24(6):1683-9. doi: 10.1185/03007990802114849. Epub 2008 May 6.
5
Moving from opacity to transparency in pharmaceutical policy.推动药品政策从不透明走向透明。
CMAJ. 2008 Feb 12;178(4):428-31. doi: 10.1503/cmaj.070799.
6
Selective publication of antidepressant trials and its influence on apparent efficacy.抗抑郁药物试验的选择性发表及其对表面疗效的影响。
N Engl J Med. 2008 Jan 17;358(3):252-60. doi: 10.1056/NEJMsa065779.
7
Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1).健康相关干预措施人体试验方案信息及结果的国际注册原则：渥太华声明（第1部分）
BMJ. 2005 Apr 23;330(7497):956-8. doi: 10.1136/bmj.330.7497.956.
8
Failing the public health--rofecoxib, Merck, and the FDA.公共卫生的失败——罗非昔布、默克公司与美国食品药品监督管理局
N Engl J Med. 2004 Oct 21;351(17):1707-9. doi: 10.1056/NEJMp048286. Epub 2004 Oct 6.
9
Clinical trial registration: a statement from the International Committee of Medical Journal Editors.临床试验注册：国际医学期刊编辑委员会的声明
Ann Intern Med. 2004 Sep 21;141(6):477-8. doi: 10.7326/0003-4819-141-6-200409210-00109. Epub 2004 Sep 8.
10
The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada.加拿大不良事件研究：加拿大医院患者中不良事件的发生率。
CMAJ. 2004 May 25;170(11):1678-86. doi: 10.1503/cmaj.1040498.
Zotero 插件